Literature DB >> 30964937

Shikimoyl-ligand decorated gold nanoparticles for use in ex vivo engineered dendritic cell based DNA vaccination.

Rakeshchandra R Meka1, Sudip Mukherjee, Chitta Ranjan Patra, Arabinda Chaudhuri.   

Abstract

Since mannose receptors (MRs) are expressed on the surfaces of dendritic cells (DCs), the most professional antigen presenting cells in our body, DNA vaccine carriers containing either covalently grafted mannosyl- or mannose-mimicking shikimoyl-ligands are being increasingly used in ex vivo DC-transfection based DNA vaccination. To this end, we have recently demonstrated that ex vivo immunization of mice with liposomes of shikimoylated cationic amphiphiles containing a 6-amino hexanoic acid spacer group in the head-group region in complexation with melanoma antigen (MART1) encoded DNA vaccine (pCMV-MART1) induces long lasting anti-melanoma immune responses (C. Voshavar, et al., J. Med. Chem., 2017, 60, 1605-1610). This finding prompted us to examine, in the present investigation, the efficacies of gold nanoparticles conjugated to the mannose-mimicking shikimoyl ligand (SL) via a 6-amino hexane thiol spacer (AuNPs-SL) for use in ex vivo DC-transfection based genetic immunization. Herein, we report on the design, synthesis, physico-chemical characterization and bioactivities of AuNPs-SL. Dynamic light scattering and transmission electron microscopy studies revealed the hydrodynamic diameters of theAuNPs-SL nanoconjugates to be within the range of 23-44 nm and their surface potentials within the range of 9-28 mV. MTT-assay showed the non-cytotoxic nature of AuNPs-SL and the findings in the electrophoretic gel retardation assays revealed strong DNA binding properties of the AuNPs-SL. Importantly, subcutaneous immunization of C57BL/6J mice with DCs ex vivo transfected with an electrostatic complex of AuNPs-SL & melanoma antigen (MART1) encoded DNA vaccine (p-CMV-MART1) induced a long lasting (100 days) anti-tumor immune response in immunized mice upon subsequent challenge with a lethal dose of melanoma. Notably, mice immunized with either autologous mbmDCs ex vivo pre-transfected with nanoplexes of shikimoylated AuNPs-SL & an irrelevant pCMV-SPORT-β-gal plasmid (without having encoded melanoma antigen) or untransfected DCs showed no lasting protection against subsequent tumor challenge. The presently described shikimoyl-decorated gold nanoparticles (AuNPs-SL) are expected to find future use in ex vivo DC-transfection based genetic immunization against cancer and other infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30964937     DOI: 10.1039/c8nr10293g

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  11 in total

Review 1.  Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.

Authors:  Johan Karlsson; Kathryn M Luly; Stephany Y Tzeng; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2021-10-27       Impact factor: 17.873

Review 2.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

3.  Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma.

Authors:  Qiushuang Zhang; Chao Xie; Dongyu Wang; Yi Yang; Hangfan Liu; Kangdong Liu; Jimin Zhao; Xinhuan Chen; Xiaoyan Zhang; Wanjing Yang; Xiang Li; Fang Tian; Ziming Dong; Jing Lu
Journal:  Cells       Date:  2019-05-22       Impact factor: 6.600

Review 4.  Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer.

Authors:  Anubhab Mukherjee; Vijay Sagar Madamsetty; Manash K Paul; Sudip Mukherjee
Journal:  Int J Mol Sci       Date:  2020-01-10       Impact factor: 5.923

Review 5.  Recent Trends of the Bio-Inspired Nanoparticles in Cancer Theranostics.

Authors:  Vijay Sagar Madamsetty; Anubhab Mukherjee; Sudip Mukherjee
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

Review 6.  Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.

Authors:  William Ho; Mingzhu Gao; Fengqiao Li; Zhongyu Li; Xue-Qing Zhang; Xiaoyang Xu
Journal:  Adv Healthc Mater       Date:  2021-01-18       Impact factor: 11.092

Review 7.  State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2.

Authors:  Mohammad Ali Derakhshan; Amir Amani; Reza Faridi-Majidi
Journal:  ACS Appl Mater Interfaces       Date:  2021-03-29       Impact factor: 9.229

8.  Targeted Delivery of Immunostimulatory CpG Oligodeoxynucleotides to Antigen-Presenting Cells in Draining Lymph Nodes by Stearic Acid Modification and Nanostructurization.

Authors:  Makoto Nagaoka; Wenqing Liao; Kosuke Kusamori; Makiya Nishikawa
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 9.  Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.

Authors:  Alexey V Baldin; Lyudmila V Savvateeva; Alexandr V Bazhin; Andrey A Zamyatnin
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

Review 10.  Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies.

Authors:  Michael Lim; Abu Zayed Md Badruddoza; Jannatul Firdous; Mohammad Azad; Adnan Mannan; Taslim Ahmed Al-Hilal; Chong-Su Cho; Mohammad Ariful Islam
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.